







Orouba Almilaji MSc 1 2, Sally D Parry MD FRCP 1, Sharon Docherty PhD 2, 
Jonathon Snook MA DPhil FRCP 1 
 
1 Gastroenterology Unit, Poole Hospital, University Hospitals Dorset, Poole, 
UK 
2 Department of Medical Science and Public Health, Bournemouth University, 
Bournemouth, UK 
 
Correspondence: Dr Jonathon Snook  
Consultant Gastroenterologist 
Poole Hospital, UHD 
Longfleet Road, Poole 
Dorset BH15 2JB   
Tel : 0044 300 0198678 












Faecal occult blood (FOB) positivity and iron deficiency anaemia (IDA) are 
common manifestations of colorectal cancer (CRC) and both potentially 
facilitate diagnosis at an earlier, more treatable stage. It has been assumed 
that both are the consequence of low-grade blood loss from the tumour bed. 
 
Method  
A retrospective analysis of 1121 cases of CRC diagnosed at a single centre 
between 2010 and 2016, comparing cases presenting via FOB-based bowel 
cancer screening programme (BCSP) and IDA pathways for a series of 
variables including age, sex, tumour location and prevalence of anaemia.  
 
Results  
The BCSP and IDA pathways each accounted for about 15% of the total case 
load. There were significant differences between the BCSP and IDA sub-
groups in median age (68 v 78 years : P<0.001), median Hb (138 v 89 g/l : 
P<0.001) and proportion of lesions in right colon (31.1% v 82.5% : P<0.001). 
The major disparity in the prevalence of anaemia (overall 20.0% v 98.2% : 
P<0.001) persisted when controlled for tumour location. 
 
Conclusion  
Paradoxically, CRC screening through the detection of FOB positivity and IDA 
identifies distinctly different sub-populations of cases. The theoretical 
implication is that an additional mechanism may be required to explain the 
development of IDA in CRC. The practical implication is that screening for IDA 





Summary box  
 
What is already known 
about this subject? 
Faecal occult blood (FOB) positivity and iron deficiency 
anaemia (IDA) are common early manifestations of 
colorectal cancer (CRC), presumed due to low-grade 
blood loss from the tumour bed. 
What are the new 
findings? 
Patients with CRC diagnosed via FOB and IDA 
pathways show significant differences in the proportion 
with right-sided cancer (31% v 82%, P<0.001) and 
anaemia (20% v 98%, P<0.001). This might imply that 
they identify distinct CRC sub-populations. 
How might it impact on 
clinical practice in the 
foreseeable future? 
The findings have theoretical implications for the 
mechanism of IDA in CRC. The major practical impact 
is support for the concept that systematic monitoring of 
at-risk populations for IDA may complement the current 
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Abbreviations  
CRC            Colorectal cancer 
IDA Iron deficiency anaemia 
Hb Blood haemoglobin concentration  
BCSP                  Bowel Cancer Screening Programme  
FOB Faecal occult blood 
gFOBt Guaiac-based faecal occult blood testing 






Colorectal cancer (CRC) is the fourth commonest cancer in the United 
Kingdom, accounting for 12% of all new cases; and the second commonest 
cause of cancer-related death, responsible for about 10% of events 1 2. 
Although the mortality from CRC is slowly falling, the 5‐year survival rate for 
CRC is still relatively poor at 58% 3 4. 
 
Because CRC may not cause symptoms until the disease is already 
advanced, the focus over recent years has been on early diagnosis by 
screening of the pre-symptomatic at-risk population 1 5. The English Bowel 
Cancer Screening Programme (BCSP) was developed with the aim of 
reducing the mortality rate 5. Guaiac-based faecal occult blood testing (gFOBt) 
was introduced in 2006 (and switched to the faecal immunochemical test (FIT) 
in 2019), the aim being to detect in stool samples the presence of small 
quantities of blood derived from the tumour bed. Bowel cancer screening by 
gFOBt has been shown to reduce the mortality rate of CRC by about 15%, 
primarily because cases are detected at an earlier stage 6-8.  
 
The second major pathway for pre-symptomatic diagnosis of CRC is through 
the detection of iron deficiency anaemia (IDA) 9-14, believed to be due to 
chronic low-grade loss of (iron-rich) blood from the tumour bed, resulting in 
the slowly progressive depletion of iron stores. As IDA often occurs before 
any other clinical manifestations of CRC 13 14, and may precede the diagnosis 
of CRC by up to 2 years 15, detection of it can also provide an opportunity to 
diagnose CRC earlier in the disease course. This is the major rationale for the 
investigation of unexplained IDA in the at-risk population on an urgent basis 
16 17.  
 
It could be argued that FOB positivity and IDA are two sides of the same coin, 




might therefore be predicted that these two approaches to the early diagnosis 
of CRC might identify broadly similar CRC sub-populations. The aim of this 
study was to assess whether this is in fact the case, by comparing the clinical 
characteristics of patients with CRC diagnosed via BCSP and IDA pathways, 





We undertook statistical analysis of anonymised clinical data for all 1258 
cases on the Poole Hospital CRC MDT database for the years 2010 to 2016 
inclusive. The data was assessed in 2018 for the purposes of a service audit 
and included: 
• age at diagnosis 
• sex 
• haemoglobin concentration (Hb) at presentation – anaemia was 
defined as an Hb below the lower limit of normal for the local laboratory 
(130 g/l for males, 115 g/l for females)  
• tumour number, histology and location(s)  
• presentation pathway - (1) symptomatic, (2) BCSP or (3) IDA 
 
For the purposes of this study, CRCs located at or distal to the splenic flexure 
were considered left-sided, whilst those proximal to splenic flexure were 
labelled right-sided. Cases with synchronous tumours were considered right-
sided if any tumour was proximal to the splenic flexure.  
All subjects in the IDA group had the diagnosis confirmed by haematinics 
according to standard criteria 14 16. Most in this group were channelled through 





The “symptomatic” presentation group comprised cases with symptoms 
relating directly to the underlying CRC (other than symptomatic anaemia) that 
resulted in GP referral or emergency admission to secondary care. Patients 
with both bowel symptoms and IDA were allocated to a presentation pathway 
based on which was felt to be the dominant feature – in a few cases this was 
rather arbitrary, but the allocation was made without knowledge of tumour site 
or stage.   
 
About 11% of cases were removed from the database after applying exclusion 
criteria (listed in Table 1). The commonest reason for exclusion due to 
incomplete data was the absence of a blood count result in the patient record. 
Of the cases remaining, 90% had histologically confirmed colorectal 
adenocarcinoma, and most of the others had high-grade dysplasia on biopsy, 
undifferentiated carcinoma, or signet cell carcinoma. In the small minority 
without histological confirmation, cases were included only if the radiological 
features were regarded as characteristic of CRC, and they were managed as 
such clinically. 
 
Pearson’s Chi-squared test was used to compare sex ratio, side proportions, 
and anaemia proportions in the IDA and BCSP groups. The Mann-Whitney 
test was used to compare age and Hb in IDA and BCSP groups. The 
significance level was set to 0.05. R (version 3.6.1) and RStudio (version 











Table 1 Exclusion criteria and numbers 
Incomplete dataset 34 
Second entry due to metachronous CRC 7 
Other neoplasm eg neuroendocrine tumour, anal 
carcinoma 
35 
Non-incident presentation, CRC diagnosed elsewhere 27 
CRC diagnosed on cancer follow-up or incidental 







After applying the exclusion criteria, 1121 cases were available for detailed 
analysis, and eight of these had synchronous CRCs. Just under 70% of cases 
presented via the symptomatic pathway, with about 15% each through the 
BCSP and IDA routes (Table 2).  
 
There was a major difference between the BCSP and IDA groups in the 
proportion of cases with anaemia at diagnosis (Table 2). The prevalence of 
anaemia in the IDA group was of course high by definition – the figure was 
98.2% rather than 100% because a small number of cases with confirmed 
iron deficiency were not anaemic by laboratory criteria. In contrast, only a 
small minority of the BCSP group were anaemic, despite being FOB positive 
by definition - the figure was 20%, compared to 46.6% for the symptomatic 





The other major difference between the BCSP and IDA groups was in the 
location of the CRCs identified. Whilst 39% presented with right-sided 
tumours overall, the proportion was markedly higher in the IDA group. Right 
sided tumours accounted for 31.6% in the symptomatic group and 31.1% in 
the BCSP group, compared to 82.5% of the IDA group (Table 2).  
 
To explore the possibility that tumour location might account for the observed 
difference in the prevalence of anaemia in the two groups, the percentage of 
cases meeting laboratory criteria for anaemia were broken down by 
presentation pathway and tumour location. Figure 1 shows that regardless of 
location, only a small minority of BCSP subjects were anaemic. 
 
Table 2 also reveals differences between the BCSP and IDA groups in terms 
of the other variables assessed. Predictably, subjects with CRC presenting 
through the BCSP pathway were younger at diagnosis. There was a trend 
towards BCSP cancers being commoner in males than females, though this 














Table 2 Descriptive statistics of the CRC dataset according to 
presentation pathway (BCSP : Bowel Cancer Screening Programme; IDA 
: iron deficiency anaemia; Q1 – Q3 : interquartile range;  Hb : 
haemoglobin concentration at diagnosis) 
 
  Symptomatic BCSP IDA 
P value 
[BCSP v IDA] 
Number 
n  
























































Figure 1 The percentage of cases with anaemia at the time of diagnosis, 











The first key observation reported here is that whilst anaemia is commonly 
associated with CRC, most cases presenting via the BCSP pathway are not 
anaemic – despite being FOB positive by definition. The literature suggests 
that conversely, the sensitivity of occult blood positivity for IDA-related CRC 
is limited. Several large case-series of FIT in the assessment of bowel-related 
indications have revealed that 10 – 15% of CRCs identified on investigation 
had a quantitative FIT < 10ug/g, and the dominant indication in this sub-group 
was IDA 18-20. In keeping with this, a limited meta-analysis suggests that 
gFOBt and FIT both have a sensitivity of 0.83 for CRC in IDA populations – 
possibly over-estimated through reporting bias 21.  
 
The second key observation is that CRC diagnosed through the IDA pathway 
appears to be quite distinct from that identified via the BCSP pathway – with 
a striking predominance of right-sided tumours, confirming previous 
observations 9-14. BCSP cancers were more commonly diagnosed in males, 
and although this didn’t reach statistical significance, it may be a relevant 
observation as men are less likely to take up the screening 8. Subjects with 
CRC presenting through the BCSP were also younger, probably reflecting 
selection by the age-groups to which screening is offered 5 8.  
 
In summary, the prevalence of anaemia in BCSP-detected tumours is 
paradoxically low, the prevalence of occult blood positivity in IDA-related 
tumours is limited, and there are major phenotypic differences between CRCs 
and subjects identified by the two pathways. This disconnect challenges the 
assumption that occult blood positivity and iron deficiency are simply parallel 
manifestations of chronic blood loss from the tumour bed in CRC, and has 





The observations require a pathophysiological explanation. Tumour location 
may be relevant, as the yield of occult blood testing 22 and faecal haemoglobin 
concentrations on quantitative FIT 18 both appear to be lower for right-sided 
CRCs. It is unclear whether this reflects differences in tumour biology, or the 
partial degeneration of haemoglobin to non-immunoreactive forms during 
passage through the colon from right-sided lesions. The persistence of 
differences in the prevalence of anaemia when controlling for the side of the 
lesion shown in the current study implies that laterality is not the whole 
explanation – although it may be a contributory factor.  
 
As the development of IDA is gradual prior to the diagnosis of CRC 15, an 
alternative explanation might be that BCSP tumours are picked up at an 
earlier stage than IDA cancers, so that although they are bleeding there has 
not been time to deplete body iron stores. However, whilst IDA-related CRC 
was historically notorious for presenting late, this may no longer be true 23.  
 
Finally, differences in tumour biology between the right and left colon 24-30 
might be relevant. One area of interest is hepcidin, a key inhibitor of dietary 
iron absorption 31 32. Functionally significant tumour release of hepcidin has 
been described 33, and limited studies to date have revealed increased 
hepcidin expression in 34-66% of colorectal cancers 34 35. It is not known 
whether this correlates with tumour location in the colon, or influences iron 
balance.  
 
The strength of this study is the population size and homogeneity, whilst 
limitations include the uncertain applicability of a single centre experience. 
Anaemia was used as a surrogate marker of iron deficiency because the 
results of iron studies were not universally available, but we feel that this was 
reasonable as iron deficiency is the dominant mechanism of anaemia in CRC 
1 9 14. Finally, the BCSP group was screened using gFOBt, as the timeframe 
was prior to the change-over to FIT – although the sensitivity of gFOBt and 




The practical implication of our findings is that as BCSP and IDA pathways 
appear to identify different CRC sub-populations, there is a case for 
introducing systematic blood count monitoring to complement the BCSP 23. 
The premise is that IDA screening would predominantly detect right-sided 
CRC, whilst the BCSP primarily targets left-sided CRC, and may be less 
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